Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: a Pilot Study
Primary Purpose
BPH, Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Moxibustion
Sponsored by
About this trial
This is an interventional treatment trial for BPH focused on measuring moxibustion
Eligibility Criteria
Inclusion Criteria:
- Male patients aged 20-80 years diagnosed with BPH with a prostate size over 20 gm
- greater than or equal to eight score on IPSS
- submit written consent
- who can understand and answer IPSS.
Exclusion Criteria:
- prostate or bladder malignancy
- received herbal medication for lower urinary tract symptoms within 1 week
- history of brain disease could cause urinary difficulty
- having problems on answering IPSS due to cognitive impairment.
- signs of acute urinary tract infection
- Diabetic mellitus
- Neurogenic bladder
Sites / Locations
- National Clinical Research Center, Korean Medicine Hospital, Pusan National University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Moxibustion
Waiting
Arm Description
A series of moxibustion sessions within four weeks from the baseline with concurrent conventional medications for BPH.
Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 4 weeks while receiving other conventional managements for BPH. After 4 weeks, if participants choose to try the moxibustion treatment, the active acupuncture treatment will be provided for 4 weeks (2 sessions/week).
Outcomes
Primary Outcome Measures
International prostate symptom score (IPSS) at 4 weeks
Secondary Outcome Measures
Patient's global impression of change (PGIC)
Maximum flow rate by uroflowmetry (Qmax)
Post-voiding residual urine in bladder (PVR)
Changing Process and Persistence of International Prostate Symptom Score (IPSS)
recruitment rate
compliance rate
the attendance rate for treatment phase in integrative group, and for three major assessments (baseline, visit 9 and visit 10)
retention rate
the ratio of 1) the number of patients who attend at the primary outcome assessment after four weeks versus the number of total participants, 2) the number of patients who attend the final assessment after 12 weeks versus the number of total participants, 3) the number of patients who returned the frequency-volume chart (FVC) versus the number of total participants.
adverse events
patients will be asked if adverse effects have developed
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02051036
Brief Title
Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: a Pilot Study
Official Title
A Pilot Study on Effectiveness and Safety of Moxibustion for Benign Prostate Hyperplasia With Lower Urinary Tract Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
February 2014 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
JUNGNAM KWON
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study aims to explore the feasibility of moxibustion as a supplementary intervention and to assess the sample size for verifying the effectiveness and safety of integrative treatment involving moxibustion compared with conventional treatment for patients with benign prostate hyperplasia (BPH) accompanying moderate to severe lower urinary tract symptoms (LUTS).
Detailed Description
Patients who diagnosed as BPH with moderate to severe LUTS aged 20 to 80 years old will be divided into two groups, one is moxibustion plus conventional therapy group and the other is conventional therapy group.
Patients who belong to moxibustion plus conventional therapy group will be treated moxibustion for eight times by a Korean Medicine doctor with conventional therapy by a urologist.
Patients who belong to conventional therapy group will be treated with conventional therapy only, and they can receive moxibustion therapy after the clinical trial is finished.
IPSS, post void residual volume (PVR) and peak urine flow (Qmax) will be checked to evaluate the effectiveness and safety.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
BPH, Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy, Lower Urinary Tract Symptom
Keywords
moxibustion
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
25 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Moxibustion
Arm Type
Experimental
Arm Description
A series of moxibustion sessions within four weeks from the baseline with concurrent conventional medications for BPH.
Arm Title
Waiting
Arm Type
No Intervention
Arm Description
Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 4 weeks while receiving other conventional managements for BPH. After 4 weeks, if participants choose to try the moxibustion treatment, the active acupuncture treatment will be provided for 4 weeks (2 sessions/week).
Intervention Type
Procedure
Intervention Name(s)
Moxibustion
Intervention Description
In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).
The moxa pillars will be removed when the patient feel hotness and require to remove them.
The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session.
Primary Outcome Measure Information:
Title
International prostate symptom score (IPSS) at 4 weeks
Time Frame
four weeks after randomization
Secondary Outcome Measure Information:
Title
Patient's global impression of change (PGIC)
Time Frame
visit 2,3,4,5,6,7,8, 9 in experimental group, visit 8,9 in control group
Title
Maximum flow rate by uroflowmetry (Qmax)
Time Frame
Baseline and 12 weeks after randomization (both group)
Title
Post-voiding residual urine in bladder (PVR)
Time Frame
Baseline and 12 weeks after randomization
Title
Changing Process and Persistence of International Prostate Symptom Score (IPSS)
Time Frame
2 weeks, 12 weeks after randomization
Title
recruitment rate
Time Frame
31-December-2015
Title
compliance rate
Description
the attendance rate for treatment phase in integrative group, and for three major assessments (baseline, visit 9 and visit 10)
Time Frame
after 12 weeks
Title
retention rate
Description
the ratio of 1) the number of patients who attend at the primary outcome assessment after four weeks versus the number of total participants, 2) the number of patients who attend the final assessment after 12 weeks versus the number of total participants, 3) the number of patients who returned the frequency-volume chart (FVC) versus the number of total participants.
Time Frame
after four weeks, after 12 weeks
Title
adverse events
Description
patients will be asked if adverse effects have developed
Time Frame
visit 1,2,3,4,5,6,7,8,9 in experimental group ; visit 1,8,9 in control group
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male patients aged 20-80 years diagnosed with BPH with a prostate size over 20 gm
greater than or equal to eight score on IPSS
submit written consent
who can understand and answer IPSS.
Exclusion Criteria:
prostate or bladder malignancy
received herbal medication for lower urinary tract symptoms within 1 week
history of brain disease could cause urinary difficulty
having problems on answering IPSS due to cognitive impairment.
signs of acute urinary tract infection
Diabetic mellitus
Neurogenic bladder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jung Nam Kwon, PhD
Organizational Affiliation
Korean Medicine Hospital, Pusan National University
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Clinical Research Center, Korean Medicine Hospital, Pusan National University
City
Yangsa
State/Province
Kyungsangnamdo
ZIP/Postal Code
626-770
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
26656981
Citation
Lee HY, Nam JK, Lee SD, Lee DH, Han JY, Yun YJ, Lee JH, Park HL, Park SH, Kwon JN. Moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a protocol for a parallel-group, randomised, controlled pilot trial. BMJ Open. 2015 Dec 11;5(12):e008338. doi: 10.1136/bmjopen-2015-008338.
Results Reference
derived
Learn more about this trial
Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: a Pilot Study
We'll reach out to this number within 24 hrs